Protagonist Therapeutics, Inc business relationships
Companies named in Protagonist Therapeutics, Inc’s 10-K filed 2026-02-25, and public companies whose annual reports name Protagonist Therapeutics, Inc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 10 / 100
- AI adoption
- 0 / 100
Layers: PeptidesGLP-1 & obesity
Named in Protagonist Therapeutics, Inc’s annual report 7
“For the year ended December 31, 2025, Takeda accounted for 100 % of the Company's revenues.” SEC filing
“Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company ("JNJ"), under a license and collaboration agreement initially entered into in 2017.” SEC filing
“In addition, the Company is eligible to receive additional worldwide development, regulatory and commercial milestone payments for rusfertide of up to $ 305.0 million, and tiered royalties from 10 % to 17 % on net sales of the Licensed Products in the Takeda Territory.” SEC filing
“Petrelintide (Zealand Pharma, in collaboration with Roche) is a long-acting amylin analog in mid-stage clinical development.” SEC filing
“We do not maintain significant rights or control of future development and commercialization activities under our collaboration with JNJ, or in ex-U.S. territories under our collaboration with Takeda.” SEC filing
“| | ● | | We rely on Takeda Pharmaceuticals USA, Inc. ("Takeda") to successfully commercialize rusfertide. |” SEC filing
- Zealand Pharma A/S (ZLDPF)Licensor-
“Research Collaboration and License Agreement with Zealand Pharma A/S” SEC filing
Companies whose annual reports name Protagonist Therapeutics, Inc 1
“*3 Partnership with Protagonist Therapeutics.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.